参考文献/References:
[1]
马丽媛,吴亚哲,陈伟伟.《中国心血管病报告2018》要点介绍[J].中华高血压杂志,2019,27(8)
:
712-716. [2] Burkhart PV,Eduardo Sabaté.Adherence to long-term therapies: evidence for action[J].Eur J Cardiovasc Nurs,2003,35(3):207. [3] Rajiv C,Hassan K,Emma H,et al.Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences[J].Eur Heart J,2013,34(38):2940-2948. [4] Ewen S,Rettig-Ewen V,Mahfoud F,et al.Drug adherence in patients taking oral anticoagulation therapy[J].Clin Res Cardiol,2014,103(3):173-182. [5] Wong MCS,Tam WWS,Cheung CSK,et al.Medication adherence to first-line antihypertensive drug class in a large Chinese population[J].Int J Cardiol,2013,167(4):1438-1442. [6] Kronish IM,Woodward M,Sergie Z,et al.Meta-analysis:impact of drug class on adherence to antihypertensives[J].Circulation,2011,123(15):1611-1621. [7] Bushnell CD,Zimmer LO,Pan W,et al.Persistence with stroke prevention medications 3 months after hospitalization[J].Arch Neurol,2015,67(12):1456-1463. [8] Bushnell CD,Olson DM,Zhao X,et al.Secondary preventive medication persistence and adherence 1 year after stroke[J].Neurology,2011,77(12):1182-1190. [9] Ullberg T,Glader EL,Zia E,et al.Associations between ischemic stroke follow-up,socioeconomic status,and adherence to secondary preventive drugs in southern sweden: observations from the swedish stroke register (Riksstroke)[J].Neuroepidemiology,2017,48(1-2):32-38. [10] Glader EL,Sjölander M,Eriksson M,et al.Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke[J]. Stroke,2010,41(2):397-401. [11] 陈艳雪,姜悦,李子孝,等.中国急性缺血性卒中及短暂性脑缺血发作二级预防药物依从性的现状[J].中国卒中杂志,2018,13(7):47-52. [12] Atkins ER,Du X,Wu Y,et al.Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors[J].Int J Cardiol,2017,241:444-449. [13] Zhang H,Yuan X,Zhang H,et al.Efficacy of long-term β-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery[J].Circulation,2015,131(25):2194-2201. [14] Menditto E,Cahir C,Aza-Pascual-Salcedo M,et al.Adherence to chronic medication in older populations: application of a common protocol among three European cohorts[J].Patient Prefer Adherence,2018,12:1975-1987. [15] Naderi SH,Bestwick JP,Wald DS.Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients[J].Am J Med,2012,125(9):882-887.e1. [16] Bagchi AD,Esposito D,Kim M,et al.Utilization of,and adherence to,drug therapy among medicaid beneficiaries with congestive heart failure[J].Clin Ther,2007,29(8):1771-1783. [17] Wu JR,Moser DK,Lennie TA,et al.Medication adherence in patients who have heart failure: a review of the literature[J].Nurs Clin North Am,2008,43(1):133-153. [18] Pallangyo P,Millinga J,Bhalia S,et al.Medication adherence and survival among hospitalized heart failure patients in a tertiary hospital in Tanzania: a prospective cohort study.[J].BMC research notes,2020,13(1):23-31. [19] Rehman ZU,Siddiqui AK,Karim M,et al.Medication non-adherence among patients with heart failure[J].Cureus,2019,11(8):e5346. [20] Jan BW,Birgit E,Thomas E.Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation[J].Ep Europace,2016,18(8):1150-1157. [21] Pham PN,Brown JD.Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?[J].BMC Cardiovasc Disord,2019,19(1):64. [22] Skeppholm M,Friberg L.Adherence to warfarin treatment among patients with atrial fibrillation.[J].Clin Res Cardiol,2014,103(12):998-1005. [23] Xiang X,Cao Y,Sun K,et al.Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China[J].Curr Med Res Opin,2017,34(2):1-17. [24] Sørensen R,Jamie NB,Langtved P J,et al.Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists[J].Eur Heart J Cardiovasc Pharmacother,2017,3(3):151-156.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]